Cancer cell biology Flashcards
What is tumour heterogeneity?
Subpopulations of cells with distinct genotypes and phenotypes, may have divergent biological behaviours
Within a primary tumour and its metasteses
What factors enable tumour heterogeneity?
Genomic and epigenomic mechanisms
Tumour microenvironment and metastasis
Clonal evolution
What are the genes involved in the onset of cancer and their normal function, and the effect of mutation?
Proto-oncogenes: Promote cell survival or proliferation. Mutated: gain of function > unregulated cell proliferation and survival
Tumour suppressor genes: Inhibit cell survival or proliferation. Mutated > loss of function mutations > unregulated cell proliferation and survival
Genome maintenance gene: repair or prevent DNA damage. Mutated: loss of function > allow mutations to accumulate
What forms of protein can result in cancer if mutated?
- Extra and intra-cellular signalling molecules
- Signal receptors
- Signal- transducing proteins
- Transcription factors
- Cell cycle control proteins (function to restrain cell prolif)
- DNA repair proteins
- Apoptotic proteins (TSGs that promote apoptosis, oncoproteins that promote cell survival)
What mutational events occur to result in gain vs loss of function of genes?
Overactivity mutation - gain of function
- single mutational event, creates oncogene
- oncogene promotes cell transformation
Underactivity mutation - loss of function
- mutational event 1, inactivates TSG
- no effect of mutation in one gene copy
- mutational event 2, inactivates second gene copy
- two inactivating mutations functionally eliminate the TSG, promoting cell transformation
What are the types of activating mutations?
Deletion or point mutation in coding sequence > hyperactive protein in normal amounts
Regulatory mutations > excessive amount of normal proteins
Gene amplification > excessive amount of normal proteins
Chromosome rearrangement > nearby regulatory DNA sequence causes overproduction of normal protein
OR > fusion to actively transcribed gene produces hyperactive fusion protein